FMP

FMP

Enter

AQST - Aquestive Therapeuti...

photo-url-https://images.financialmodelingprep.com/symbol/AQST.png

Aquestive Therapeutics, Inc.

AQST

NASDAQ

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

2.47 USD

0.05 (2.02%)

Free Cash Flow

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

34.03M

49.06M

67.81M

76.69M

66.32M

79.92M

96.3M

116.04M

139.82M

168.48M

Revenue %

-

44.19

38.22

13.1

-13.52

20.5

20.5

20.5

20.5

Operating Cash Flow

-10.22M

-5.75M

985.58k

-11.28M

-4.4M

-9.85M

-11.87M

-14.3M

-17.23M

-20.77M

Operating Cash Flow %

-30.02

-11.72

1.45

-14.71

-6.63

-12.33

-12.33

-12.33

-12.33

Cap Ex

-2.62M

-3.29M

-8.98M

-4.33M

-2.6M

-5.95M

-7.17M

-8.64M

-10.41M

-12.54M

Cap Ex %

-7.71

-6.71

-13.24

-5.64

-3.92

-7.44

-7.44

-7.44

-7.44

Free Cash Flow

-12.84M

-9.04M

-7.99M

-15.61M

-7M

-15.8M

-19.04M

-22.94M

-27.64M

-33.31M

Weighted Average Cost Of Capital

Price

0.15

Beta

Diluted Shares Outstanding

25.33M

Costof Debt

7.57

Tax Rate

After Tax Cost Of Debt

7.57

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

35M

Total Equity

3.75M

Total Capital

38.75M

Debt Weighting

90.33

Equity Weighting

9.67

Wacc

7.33

Build Up Free Cash Flow

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

34.03M

49.06M

67.81M

76.69M

66.32M

79.92M

96.3M

116.04M

139.82M

168.48M

Operating Cash Flow

-10.22M

-5.75M

985.58k

-11.28M

-4.4M

-9.85M

-11.87M

-14.3M

-17.23M

-20.77M

Cap Ex

-2.62M

-3.29M

-8.98M

-4.33M

-2.6M

-5.95M

-7.17M

-8.64M

-10.41M

-12.54M

Free Cash Flow

-12.84M

-9.04M

-7.99M

-15.61M

-7M

-15.8M

-19.04M

-22.94M

-27.64M

-33.31M

Wacc

7.33

7.33

7.33

7.33

7.33

Pv Lfcf

-14.72M

-16.53M

-18.55M

-20.83M

-23.39M

Sum Pv Lfcf

-94.02M

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

7.33

Free Cash Flow T1

-33.97M

Terminal Value

-637.47M

Present Terminal Value

-447.58M

Intrinsic Value

Enterprise Value

-541.6M

Net Debt

29.28M

Equity Value

-570.87M

Diluted Shares Outstanding

25.33M

Equity Value Per Share

-22.54

Projected DCF

-22.54 1.007%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep